LION bioscience Releases SRS Gateway for Oracle
back to LION bioscience home
SitemapPrintable version of this documentContact LIONZur deutschen Version dieses Dokuments LION bioscience AG
Press Releases
Ad-Hoc Releases
Online Press Kit
Photos & Logos
PR Contact

© 2004 LION bioscience AG
Contact Webmaster
LION bioscience Releases SRS Gateway for Oracle
  • SRS Gateway for Oracle to provide SQL querying of SRS from any Oracle environment

Cambridge, MA, USA, Heidelberg, Germany, January 21, 2004 – LION bioscience (Nasdaq: LEON) announced today immediate availability of the SRS Gateway for Oracle. The new module of the SRS architecture combines the power of two industry-leading platforms, SRS and the Oracle Database, providing scientists and informatics professionals optimal integration capabilities for discovery-relevant data of all file types and sources.

The new LION SRS Gateway for Oracle enables informatics professionals to access the SRS engine and associated databases from Oracle using SQL or from any Oracle application. Oracle users in the life sciences industry can use the new product to access more than 900 different public flat file databases and integrate the data into their existing infrastructures using the power of SRS. The SRS Gateway for Oracle is available immediately for SRS 7.1 and supports Oracle9i Database Release 2 and subsequent versions including Oracle Database 10g.

“LION is responding to strong customer demand by bringing SRS and Oracle closer together,” said Dr. Daniel Keesman, LION bioscience Chief Business Officer. “With the successful launch of the SRS Gateway for Oracle, we continue our efforts and commitment to delivering open, industry-standard solutions that leverage ‘best of breed’ technologies. The combination of Oracle and SRS 7.1 integrates and makes accessible the largest and most wide-spread databases in the Life Sciences with virtually one mouse click.”

“Until the release of the SRS Gateway, combining flat files with relational databases was a major challenge for the life science industry. However, with the SRS Gateway for Oracle, our users will have access to broader data sets including the numerous public flat file databases,” said Jacek Myczkowski, Oracle Vice President - Life Sciences and Data Mining Technologies. “We chose to work with LION because we see SRS as one of the best ways to integrate biological data. Furthermore, we expect this partnership with LION will be of great benefit to the life science industry and will decrease the time and money needed for drug discovery.”

About SRS

SRS is a proven, scalable and robust data integration platform that provides fast access to diverse life science data - genetic, protein, cellular, molecular and clinical - from public and proprietary sources, regardless of data format. SRS is used in more than 300 commercial and academic sites delivering genomic data daily to thousands of users around the globe. SRS is the clear market leader for bioinformatics data integration, providing global bioinformatics platforms for pharmaceutical companies such as Eli Lilly, Johnson&Johnson and AstraZeneca, as well as forming the basis of genomics portals for leading data providers such as Celera, Incyte, Derwent and Affymetrix.

About Oracle

Oracle is the world’s largest enterprise software company. For more information about Oracle visit our website at

Oracle is a registered trademark of Oracle Corporation and or its affiliates.

For further information please contact:

LION bioscience:
Julia Fritz
Corporate Communications
+49 (0) 6221 4038 158

Oracle Corp:
Ryan Mikolasik
Director, Industries and Customer PR
Corporate Communications
+1 650 607 5087

About LION bioscience AG

LION bioscience (ISIN: DE0005043509, Reuters: LIOG, Bloomberg: LIO, Nasdaq: LEON) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. LION’s performance software solutions developed by its scientific and IT experts enable researchers to simultaneously compile and analyze data across various phases of the R&D process. Research time and costs are reduced, as scientists are able to identify and focus on the most promising drug candidates earlier.

LION ( sets the standard for integration solutions with more than 300 corporate and academic customers globally including AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, Eli Lilly, GlaxoSmithKline, IBM, Incyte, Johnson&Johnson, Merck Inc., Nestlé, Novartis, Schering AG and Sumitomo Pharmaceuticals. LION’s solutions include SRS for bioinformatics data access, iDEA pkEXPRESSä with analysis and prediction tools for ADME/tox, LION Target Engine™ for target identification and optimization, LION Lead Engine™ for lead identification and optimization, LION DiscoveryCenter™ for biological and chemical data and application integration and LION SolutionCenter™ for professional services.


Except for the historical information contained herein, the matters set forth in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, and other applicable U.S. and German laws. These forward-looking statements may include projections, estimates, targets, goals and descriptions of future events. Such statements are based on the current targets that LION has set itself and on LION’s current expectations, each of which is subject to risks and uncertainties. LION’s actual results may vary materially from those targeted, expected or projected because of factors such as uncertainties relating to technologies, product and solution development, acceptance by the market of LION’s offerings, market or industry trends, success of LION’s business model and strategy, competition, exchange rate fluctuations, cost or pricing of LION’s products and solutions, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent or copyright protection and litigation. We refer you to LION’s Annual Reports on Form 20-F, as filed with the Securities and Exchange Commission (SEC), as well as LION’s SEC filing, as filed on September 30, 2003, in which these and other risk factors are discussed. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained in this announcement, whether as a result of new information, change of assumptions or business model, future developments or otherwise. LION bioscience®, Life Science Informatics™, LION DiscoveryCenter™, LION SolutionCenter™, LION Hosted Services™, LION Target Engine™, LION Lead Engine™, LSI™, bioSCOUT®, arraySCOUT™, arrayTAG™, arrayBASE™, genomeSCOUT™, pathSCOUT™, πSCOUT™ and iDEA™ are either registered trademarks of LION bioscience AG or its subsidiaries in the United States and/or other countries, or there are pending applications by LION bioscience AG or its subsidiaries for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners.

Download as Word Document
Download as PDF Document